Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Operating Leases (2019 - 2026)

C4 Therapeutics has reported Operating Leases over the past 8 years, most recently at $51.9 million for Q1 2026.

  • For Q1 2026, Operating Leases fell 11.16% year-over-year to $51.9 million; the TTM value through Mar 2026 reached $51.9 million, down 11.16%, while the annual FY2025 figure was $53.6 million, 10.61% down from the prior year.
  • Operating Leases for Q1 2026 was $51.9 million at C4 Therapeutics, down from $53.6 million in the prior quarter.
  • Over five years, Operating Leases peaked at $75.2 million in Q2 2022 and troughed at $51.9 million in Q1 2026.
  • A 5-year average of $64.1 million and a median of $64.4 million in 2024 define the central range for Operating Leases.
  • Biggest five-year swings in Operating Leases: soared 569.59% in 2022 and later fell 11.16% in 2026.
  • Year by year, Operating Leases stood at $71.0 million in 2022, then decreased by 7.35% to $65.8 million in 2023, then decreased by 8.78% to $60.0 million in 2024, then decreased by 10.61% to $53.6 million in 2025, then decreased by 3.15% to $51.9 million in 2026.
  • Business Quant data shows Operating Leases for CCCC at $51.9 million in Q1 2026, $53.6 million in Q4 2025, and $55.2 million in Q3 2025.